Background: Runt domain transcription factor 3 (Runx3) is a putative tumor suppressor in human neoplasia. Previous researches suggested that a lack of Runx3 function contributed to human gastric carcinogenesis, however, it is not clear whether Runx3 is closely associated with clinicopathological features of primary stomach tumor and survival rate of patients. Aims: The article is to investigate the influence of survival analysis on Runx3 gene expression in the primary stomach tumor. Methods: Runx3 mRNA expression was detected in 108 primary gastric tumors and non-tumor tissue by semiquantitative reverse transcription-PCR (RT-PCR). All patients were followed up more than five years after radical gastrectomy. Results: There was a loss or substantial decrease of Runx3 mRNA expression in 108 cases of gastric tumors as compared with that in normal gastric mucosa (p<0.001). According to the gray scale median of Runx3 mRNA in primary tumors, the 108 cases were separated into two groups: The lower expressing group (≤0.403) and the over one (>0.403). By comparing analysis of clinical information between two groups, it was found that the lower expression of Runx3 mRNA in the primary tumor was not only associated with the poor clinicopathological factors, but also the inferior survival duration and cumulative survival rate of patients (p<0.05). Conclusions: These results strongly suggest that Runx3 was an independent prognostic factor and a potential therapeutic target for gastric cancer.
Cite this paper
H. Xu, G. Xu, Q. Zhang, G. Qu, Y. Yu and Y. Jiang, "The Influence of Survival Analysis on Runx3 Gene Expression in the Primary Tumor of Patients Suffering from Stomach Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 1, 2013, pp. 43-48. doi: 10.4236/jct.2013.41A006.
 F. Pasini, A. P. Fraccon and G. D. E. Manzoni, “The Role of Chemotherapy in Metastatic Gastric Cancer,” Anticancer Research, Vol. 31, No. 10, 2011, pp. 3543-3554.
 V. Catalano, R. Labianca, G. D. Beretta, G. Gatta, F. de Braud and E. Van Cutsem, “Gastric Cancer,” Critical Reviews in Oncology/Hematology, Vol. 71, No. 2, 2009, pp. 127-164. doi:10.1016/j.critrevonc.2009.01.004
 Y. Ito, “Oncogenic Potential of the Runx Gene Family: ‘Overview’,” Oncogene, Vol. 23, No. 24, 2004, pp. 4198-4208. doi:10.1038/sj.onc.1207755
 S. C. Bae and J. K. Choi, “Tumor Suppressor Activity of Runx3,” Oncogene, Vol. 23, No. 24, 2004, pp. 4336-4340.
 K. Blyth, E. R. Cameron and J. C. Neil, “The Runx Genes: Gain or Loss of Function in Cancer,” Nature Reviews Cancer, Vol. 5, No. 5, 2005, pp. 376-387.
 Y. Ito, “Runx Genes in Development and Cancer: Regulation of Viral Gene Expression and the Discovery of Runx Family Genes,” Advances in Cancer Research, Vol. 99, 2008, pp. 33-76.
 Y. Nakase, C. Sakakura, K. Miyagawa, et al., “Frequent Loss of Runx3 Gene Expression in Remnant Stomach Cancer and Adjacent Mucosa with Special Reference to Topography,” British Journal of Cancer, Vol. 92, No. 3, 2008, pp. 562-569.
 B. G. Jang and W. H. Kim, “Molecular Pathology of Gastric Carcinoma,” Pathobiology, Vol. 78, No. 6, 2011, pp. 302-310. doi:10.1159/000321703
 J. P. Hamilton, and S. J. Meltzer, “A Review of the Genomics of Gastric Cancer,” Clinical Gastroenterology and Hepatology, Vol. 4, No. 4, 2006, pp. 416-425.
 H. Shiraha, S. Nishina and K. Yamamoto, “Loss of Runt-Related Transcription Factor 3 Causes Development and Progression of Hepatocellular Carcinoma,” Journal of Cellular Biochemistry, Vol. 112, No. 3, 2011, pp. 745-749. doi:10.1002/jcb.22973
 N. Yanagawa, G. Tamura, H. Oizumi, et al., “Promoter Hypermethylation of RASSF1A and Runx3 Genes as an Independent Prognostic Prediction Marker in Surgically Resected Non-Small Cell Lung Cancers,” Lung Cancer, Vol. 58, No. 1, 2007, pp. 131-138.
 E. J. Kim, Y. J. Kim, P. Jeong, Y. S. Ha, S. C. Bae and W. J. Kim, “Methylation of the Runx3 Promoter as a Potential Prognostic Marker for Bladder Tumor,” Journal of Urology, Vol. 180, No. 3, 2008, pp. 1141-1145.
 D. Wei, W. Gong, S. C. Oh, et al., “Loss of Runx3 Expression Significantly Affects the Clinical Outcome of Gastric Cancer Patients and Its Restoration Causes Drastic Suppression of Tumor Growth and Metastasis,” Cancer Research, Vol. 65, No. 11, 2005, pp. 4809-4816.
 Y. Tokumaru, S. Nomoto, C. Jeronimo, et al., “Biallelic Inactivation of the RIZ1 Gene in Human Gastric Cancer,” Oncogene, Vol. 22, No. 44, 2003, pp. 6954-6958.
 A. Goel, C. N. Arnold, P. Tassone, et al., “Epigenetic Inactivation of Runx3 in Microsatellite Unstable Sporadic Colon Cancers,” International Journal of Cancer, Vol. 112, No. 5, pp. 754-759. doi:10.1002/ijc.20472
 D. Levanon, Y. Bernstein, V. Negreanu, K. R. Bone, A. Pozner, R. Eilam, J. Lotem, O. Brenner and Y. Groner, “Absence of Runx3 Expression in Normal Gastrointestinal Epithelium Calls into Question Its Tumour Suppressor Function,” EMBO Molecular Medicine, Vol. 3, No. 10, 2011, pp. 593-604.
 T. Y. Kim, H. J. Lee, K. S. Hwang, et al., “Methylation of Runx3 in Various Types of Human Cancers and Premalignant Stages of Gastric Carcinoma,” Laboratory Investigation, Vol. 84, No. 4, 2004, pp. 479-484.
 W. J. Kim, “Runx3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors,” Cancer Research, Vol. 65, No. 20, 2005, pp. 9347-9354.
 M. Suzuki, H. Suzuki, Y. Minegishi, K. Ito, T. Nishizawaand and T. Hibi, “H. Pylori-Eradication Therapy Increases Runx3 Expression in the Glandular Epithelial Cells in Enlarged-Fold Gastritis,” Journal of Clinical Biochemistry and Nutrition, Vol. 46, No. 3, 2010, pp. 259-264.